Generic Name and Formulations:
Vortioxetine 5mg, 10mg, 20mg; tabs.
Takeda and Lundbeck
Indications for TRINTELLIX:
Treatment of major depressive disorder.
Initially 10mg once daily; then, increase to 20mg/day, as tolerated. May consider 5mg/day if unable to tolerate. Discontinuing treatment: may reduce to 10mg/day for one week before full discontinuation of 15mg/day or 20mg/day. CYP2D6 poor metabolizers: max 10mg/day. Concomitant strong CYP2D6 inhibitors: reduce vortioxetine dose by ½; increase to original dose when inhibitor is discontinued. Concomitant strong CYP inducers for >14 days: consider increasing vortioxetine dose up to max 3x original dose; reduce to original dose within 14 days when inducer is discontinued.
<18yrs: not established.
During or within 14 days of MAOIs; do not start an MAOI during or within 21 days of vortioxetine. Concomitant linezolid or IV methylene blue.
Suicidal thoughts and behaviors.
Increased risk of suicidal thoughts and behavior in children, adolescents, and young adults; monitor for clinical worsening or behavior changes in all patients. Monitor for serotonin syndrome; discontinue if occurs. History of mania/hypomania. Screen for bipolar disorder prior to starting. Angle-closure glaucoma. Volume depletion. Elderly. Pregnancy (Cat.C; see full labeling for effects on neonates with 3rd trimester exposure). Nursing mothers.
Serotonergic agonist and antagonist.
See Contraindications. Increased risk of serotonin syndrome with other serotonergic drugs (eg, triptans, TCAs, fentanyl, lithium, tramadol, tryptophan, buspirone, amphetamines, St. John's Wort) or with drugs that impair serotonin metabolism (eg, MAOIs, linezolid, IV methylene blue). If linezolid or IV methylene blue necessary, discontinue vortioxetine before starting; monitor for serotonin syndrome for 21 days or until 24hrs after last dose of linezolid or IV methylene blue, whichever comes first. Increased risk of bleeding with NSAIDs, aspirin, warfarin, others that affect coagulation. May be affected by strong CYP2D6 inhibitors (eg, bupropion, fluoxetine, paroxetine, quinidine) or strong CYP inducers (eg, rifampin, carbamazepine, phenytoin); adjust doses (see Adults). May potentiate protein-bound drugs.
Nausea, constipation, vomiting, dizziness; hyponatremia (esp. elderly), mania/hypomania, sexual dysfunction.
Formerly known as Brintellix.
Tabs—30, 90, 500
Clinical Pain Advisor Articles
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Suprazygomatic Sphenopalatine Ganglion Block May Quickly Relieve Status Migrainosus Pain
- Reducing Mortality After Overdose: Is Treatment for Opioid Use Disorder Effective?
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- Low Literacy Self-Management Program for Chronic Pain May Be Effective
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- FDA Approves Minimally-Invasive, Non-Drug Therapy for Pain Management
- Chronic Migraine and Medication Overuse Headache Linked to Stress
- Set of Personality Traits May Predict Prescription Drug Use, Misuse in Young Adults
- The Opioid Crisis: District by District
- Opioid Administration, Prescribing in the ED on the Decline in Recent Years